Integra LifeSciences Q3 Adjusted Earnings, Revenue Rise

Integra LifeSciences reported Q3 adjusted earnings and revenue growth. The company expects 2026 revenue between $1.63B and $1.65B, slightly below FactSet's estimate of $1.66B. The stock has seen a 5-day change of 13.33 USD and a year-to-date change of -3.75%.

Original reporting
Published Oct 21, 2026, 10:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The revenue shortfall relative to consensus may trigger short‑term sell pressure, but the adjusted earnings beat could soften the decline.

02

Market read

Earnings release is a primary catalyst for the stock and may influence the broader med‑tech sector.

03

What to watch

Potential upside from upcoming product launches not reflected in the current guidance.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences (IART) is a medical device and regenerative medicine company. The Q3 earnings release provides the latest financial performance metrics.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences reported Q3 adjusted earnings and a revenue range of $1.63B‑$1.65B, slightly below the $1.66B consensus.

Expected impact

likely pressure as the market prices in the revenue shortfall

Evidence & confidence

Revenue guidance undercuts consensus; investors typically react negatively to earnings below expectations.

Market effects

Medical device sector may see modest downside pressure from a key player missing revenue expectations.

U.S. healthcare stocks could see slight pullback in early trading.

Limited to investors tracking U.S. med‑tech earnings season.

Counterpoint

If the company’s cost structure improves, the earnings beat could be a buying opportunity on a dip.

Key entities

  • Integra LifeSciences

    Medical device and regenerative medicine firm reporting Q3 results.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.